CO4900070A1 - NUEVOS DERIVADOS DE ACIDO CARBONICO, SU PRODUCCION Y APLICA- CION COMO ANTAGONISTAS MIXTOS DE RECEPTORES ET(sub A)/ET- (sub B) - Google Patents
NUEVOS DERIVADOS DE ACIDO CARBONICO, SU PRODUCCION Y APLICA- CION COMO ANTAGONISTAS MIXTOS DE RECEPTORES ET(sub A)/ET- (sub B)Info
- Publication number
- CO4900070A1 CO4900070A1 CO97051479A CO97051479A CO4900070A1 CO 4900070 A1 CO4900070 A1 CO 4900070A1 CO 97051479 A CO97051479 A CO 97051479A CO 97051479 A CO97051479 A CO 97051479A CO 4900070 A1 CO4900070 A1 CO 4900070A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- substituted
- phenyl
- alkenyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Abstract
Derivados de ácido carbónico de la fórmula I:CARACTERIZADOS porqueR1 significa tetrazol o a un grupo en el que R tiene el siguiente significado: a) un residuo OR7 , en donde R7 significa: hidrógeno, el catión de un metal alcalino, el catión de un metal alcalinotérreo, o un ión amonio fisiológicamente compatible;C3 -C8 cicloalquilo, C1 -C8 alquilo, CH2 -fenilo, que puede ser sustituido Un C3 -C6 -alquenilo o un grupo C3 -C6 -alquinilo, que puede ser sustituido o fenilo, en caso dado, sustituido. b) un heteroaromato de 5 eslabones ligado con un átomo de nitrógeno, c) un grupo en el que k toma los valores 0, 1 y 2, p los calores 1, 2, 3 y 4 y R8 representa C1 -C4 -alquilo, - 2 -C3 -C8 -cicloalquilo, C3 -C6 -alquenilo, C3 -C6-alquinilo o fenilo, que puede ser sustituido d) un residuo en el que R9 significa: C1 -C4 -alquilo, C3 -C6 -alquenilo, C3 -C6 -alquinilo, C3 -C8 -cicloalquilo, donde estos residuos pueden tener un residuo C1 -C4 -alcoxi, C1 -C4 -alquiltio y/o un residuo de fenilo fenilo en caso de ser necesario sustituido e) un residuo.en donde R13 y R14 pueden ser iguales o diferentes y tienen el siguiente significado: hidrógeno, C1 -C8 -alquilo, C3 -C8 -cicloalquilo, C3 -C8 -alquenilo, C3 -C8 -alquinilo, bencilo, fenilo que puede ser sustituido o R13 y R14 forman juntos una cadena C4 -C7 -alquileno cerrada la cual puede ser sustituida, que, puede contener un heteroátomo R2 hidrógeno, hidrozi, NH2 NH(C1 -C4 -alquilo), N(C1 -C4 -alquilo)2 , halógeno, C1 -C4 -alquilo, C2 -C4 -alquenilo, C2 -C4 -alquinilo, C1 -C4 -hidroxialquilo, C1 -C4 -alquilo halógeno, C1 -C4 -alcoxi, C1 -C4 -alcoxi halógeno o C1 -C4 -alquiltio, o CR2 está unido con CR10 como se indica abajo en un anillo de 5 a 6 eslabonesX nitrógeno o metilo. Y nitrógeno o metilo Z nitrógeno o CR10 , en donde CR10 significa hidrógeno o C1 -C4 -alquilo o CR10 junto con CR2 o CR3 forma un anillo de alquileno de 5 o 6 eslabones o de alquenilo, que puede ser sustituido y en donde uno o más grupos metilenos pueden ser sustituidos por oxígeno, azufre - NH o N(C1 -C4 -alquilo) R3 hidrógeno, hidroxi, NH2 , NH (C1 -C4 -alquilo), N(C1 -C4 -alquilo)2 , halógeno, C1 -C4 -alquilo, C2 -C4 -alquenilo, C2 -C4 -alquinilo, C1 -C4 -alquilo halógeno, C1 -C4 -alcoxi, C1 -C4 -alcoxi halógeno, C1 -C4 -alquiltio o CR3 está unido con CR10 tal como se indica arriba en un anillo de 5 o 6 eslabones. R4 y R5 (que pueden ser iguales o distintos): fenilo o naftilo, que pueden ser sustituidos, o fenilo o naftilo, que pueden estar unidos en posición orto por una unión directa a un grupo metileno, etileno o etenileno, a un átomo de oxígeno o azufre o a un grupo SO2 , NHAND#8209; o NAND#8209;alquilo; C3 AND#8209;C8 AND#8209;cicloalquilo, en caso necesario, sustituido R6 en caso necesario C3 AND#8209;C8 AND#8209;cicloalquilo sustituido fenilo o naftilo, que pueden ser sustituidos en heteroaromato de cinco a seis eslabones conteniendo de uno a tres átomos de nitrógeno y/o átomo de azufre u oxígeno, que puede ser sustituidoW azufre y oxígenoQ Un distanciador que en su largo corresponda a una cadena C2 AND#8209;C4 . así como las sales fisiológicamente compatibles y las formas enantiómeras y diastereómeras.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19636046A DE19636046A1 (de) | 1996-09-05 | 1996-09-05 | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4900070A1 true CO4900070A1 (es) | 2000-03-27 |
Family
ID=7804712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO97051479A CO4900070A1 (es) | 1996-09-05 | 1997-09-04 | NUEVOS DERIVADOS DE ACIDO CARBONICO, SU PRODUCCION Y APLICA- CION COMO ANTAGONISTAS MIXTOS DE RECEPTORES ET(sub A)/ET- (sub B) |
Country Status (22)
Country | Link |
---|---|
US (1) | US6670367B1 (es) |
EP (1) | EP0929529A2 (es) |
JP (1) | JP2000517329A (es) |
KR (1) | KR20000068446A (es) |
CN (1) | CN1236362A (es) |
AR (1) | AR009543A1 (es) |
AU (1) | AU736414B2 (es) |
BG (1) | BG103258A (es) |
BR (1) | BR9711693A (es) |
CA (1) | CA2265504A1 (es) |
CO (1) | CO4900070A1 (es) |
DE (1) | DE19636046A1 (es) |
HU (1) | HUP0000664A3 (es) |
ID (1) | ID19417A (es) |
IL (1) | IL128743A0 (es) |
NO (1) | NO312674B1 (es) |
NZ (1) | NZ334548A (es) |
PL (1) | PL331998A1 (es) |
SK (1) | SK25999A3 (es) |
TR (1) | TR199900486T2 (es) |
WO (1) | WO1998009953A2 (es) |
ZA (1) | ZA977946B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6030975A (en) * | 1997-03-14 | 2000-02-29 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use in treating cancer |
CA2302350A1 (en) * | 1997-09-04 | 1999-03-11 | Basf Aktiengesellschaft | Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists |
ATE257706T1 (de) * | 1997-09-26 | 2004-01-15 | Abbott Gmbh & Co Kg | Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate |
DE19743143A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
DE69830069T3 (de) * | 1997-10-17 | 2012-02-09 | Ark Therapeutics Ltd. | Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel |
DE19809144A1 (de) * | 1998-03-04 | 1999-09-09 | Basf Ag | Neue unsymmetrisch substituierte Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶LAMBDA¶/ET¶B¶-Rezeptorantagonisten |
DE19836044A1 (de) * | 1998-08-10 | 2000-02-17 | Basf Ag | Neue Carbonsäurederivate, die Ketoseitenketten tragen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten |
US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
DE19933164A1 (de) * | 1999-07-20 | 2001-01-25 | Basf Ag | Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten |
DE19951671A1 (de) * | 1999-10-27 | 2001-05-03 | Basf Ag | 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist |
DE10064797A1 (de) * | 2000-12-22 | 2002-06-27 | Knoll Ag | Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon |
US20030152956A1 (en) * | 2000-12-26 | 2003-08-14 | Noriko Ohtani | Method of examining allergic disease |
PT1243262E (pt) | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
DK1243263T3 (da) | 2001-03-21 | 2003-03-17 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte |
CA2562937A1 (en) | 2004-04-16 | 2005-10-27 | Schwarz Pharma Ag | Use of peptidic compounds for the prophylaxis and treatment of chronic headache |
EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
EA014055B1 (ru) | 2004-08-27 | 2010-08-30 | Шварц Фарма Аг | Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами |
US20080076812A1 (en) * | 2006-03-13 | 2008-03-27 | Jinling Chen | Formulations of sitaxsentan sodium |
KR20080104149A (ko) * | 2006-03-13 | 2008-12-01 | 엔싸이시브 파마슈티칼즈 인코퍼레이티드 | 확장기 심장 부전의 치료를 위한 방법 및 조성물 |
TWI397417B (zh) | 2006-06-15 | 2013-06-01 | Ucb Pharma Gmbh | 具有協同抗驚厥功效之醫藥組成物 |
US20080026061A1 (en) * | 2006-06-22 | 2008-01-31 | Reichwein John F | Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide |
CN103709106A (zh) * | 2013-12-06 | 2014-04-09 | 石家庄博策生物科技有限公司 | 一种立体选择性制备安立生坦的方法 |
CN103739557B (zh) * | 2013-12-30 | 2015-10-21 | 黄河三角洲京博化工研究院有限公司 | 一种4,6-二甲基-2-甲磺酰基嘧啶的合成方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4313413A1 (de) * | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryloxy(thio)-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
DE4313412A1 (de) * | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
DE4335950A1 (de) | 1993-10-21 | 1995-04-27 | Basf Ag | Derivate von 3-Hydroxycarbonsäuren, deren Herstellung und Verwendung |
DE4411225A1 (de) | 1994-03-31 | 1995-10-05 | Basf Ag | Verwendung von Carbonsäurederivaten als Arzneimittel |
DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
DE19536891A1 (de) | 1995-10-04 | 1997-04-10 | Basf Ag | Neue Aminosäurederivate, ihre Herstellung und Verwendung |
-
1996
- 1996-09-05 DE DE19636046A patent/DE19636046A1/de not_active Withdrawn
-
1997
- 1997-03-02 US US09/254,137 patent/US6670367B1/en not_active Expired - Fee Related
- 1997-09-02 KR KR1019997001815A patent/KR20000068446A/ko not_active Application Discontinuation
- 1997-09-02 NZ NZ334548A patent/NZ334548A/xx unknown
- 1997-09-02 IL IL12874397A patent/IL128743A0/xx unknown
- 1997-09-02 TR TR1999/00486T patent/TR199900486T2/xx unknown
- 1997-09-02 EP EP97943819A patent/EP0929529A2/de not_active Withdrawn
- 1997-09-02 CN CN97199458A patent/CN1236362A/zh active Pending
- 1997-09-02 HU HU0000664A patent/HUP0000664A3/hu unknown
- 1997-09-02 AU AU45524/97A patent/AU736414B2/en not_active Ceased
- 1997-09-02 JP JP10512203A patent/JP2000517329A/ja active Pending
- 1997-09-02 CA CA002265504A patent/CA2265504A1/en not_active Abandoned
- 1997-09-02 PL PL97331998A patent/PL331998A1/xx unknown
- 1997-09-02 SK SK259-99A patent/SK25999A3/sk unknown
- 1997-09-02 WO PCT/EP1997/004688 patent/WO1998009953A2/de not_active Application Discontinuation
- 1997-09-02 BR BR9711693A patent/BR9711693A/pt not_active IP Right Cessation
- 1997-09-04 ZA ZA977946A patent/ZA977946B/xx unknown
- 1997-09-04 CO CO97051479A patent/CO4900070A1/es unknown
- 1997-09-05 ID IDP973110A patent/ID19417A/id unknown
- 1997-09-05 AR ARP970104059A patent/AR009543A1/es not_active Application Discontinuation
-
1999
- 1999-03-04 NO NO19991079A patent/NO312674B1/no not_active IP Right Cessation
- 1999-03-16 BG BG103258A patent/BG103258A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2265504A1 (en) | 1998-03-12 |
HUP0000664A2 (hu) | 2001-04-28 |
ID19417A (id) | 1998-07-09 |
HUP0000664A3 (en) | 2001-07-30 |
NO991079D0 (no) | 1999-03-04 |
PL331998A1 (en) | 1999-08-16 |
ZA977946B (en) | 1999-03-04 |
WO1998009953A3 (de) | 1998-10-29 |
NO991079L (no) | 1999-05-04 |
EP0929529A2 (de) | 1999-07-21 |
AR009543A1 (es) | 2000-04-26 |
BG103258A (en) | 2000-12-29 |
KR20000068446A (ko) | 2000-11-25 |
CN1236362A (zh) | 1999-11-24 |
BR9711693A (pt) | 1999-08-24 |
JP2000517329A (ja) | 2000-12-26 |
WO1998009953A2 (de) | 1998-03-12 |
SK25999A3 (en) | 1999-09-10 |
AU736414B2 (en) | 2001-07-26 |
DE19636046A1 (de) | 1998-03-12 |
US6670367B1 (en) | 2003-12-30 |
AU4552497A (en) | 1998-03-26 |
IL128743A0 (en) | 2000-01-31 |
TR199900486T2 (xx) | 1999-06-21 |
NO312674B1 (no) | 2002-06-17 |
NZ334548A (en) | 2000-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4900070A1 (es) | NUEVOS DERIVADOS DE ACIDO CARBONICO, SU PRODUCCION Y APLICA- CION COMO ANTAGONISTAS MIXTOS DE RECEPTORES ET(sub A)/ET- (sub B) | |
ES2182535T3 (es) | Derivados de benzo(b)tiepina-1,-dioxido, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion. | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
CR7865A (es) | Derivados de dihidropiranoindol -3,4-diona sustituidos y derivados de 2-hidroximetilindol del acido 3-oxoacetico sustituidos como inhibidores del inhibidor del activador del plasminogeno 1(pai-1) | |
UY28823A1 (es) | Compuestos de ácido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1 | |
CO5611123A2 (es) | Cumarinas utiles como biomarcadores | |
AR043049A1 (es) | Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica | |
ES2100187T3 (es) | Derivados de carboestirilos y composiciones farmaceuticas que los contienen. | |
CO5070570A1 (es) | DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE | |
AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
CO5160347A1 (es) | Derivados de acido carbamico | |
ES2113927T3 (es) | Compuestos utiles como antagonistas de leucotrienos. | |
CO5630034A2 (es) | Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
ES2039242T3 (es) | Un procedimiento para la preparacion de nuevos derivados de piperidina. | |
ECSP014097A (es) | Derivados de tiofeno utiles como agentes anticancerosos | |
AR245447A1 (es) | Procedimiento para preparar derivados de 2,4-diamino-5-(biciclo-sustituido)metilpirimidinas. | |
ES2190115T3 (es) | Derivados de acido hidroxamico y carboxilico con actividad inhibidora de mmp y tnf. | |
ES2127524T3 (es) | Derivados de benzamida como antagonistas de vasopresina. | |
AR245933A1 (es) | Procedimiento para preparar compuestos de 4-(3-hidroxifenil)metil-3-alquil-n-alquilpiperidina y sus sales. | |
CO4900040A1 (es) | Nuevos derivados de acidos alfa-hidroxi su preparacion y aplicacion | |
CO5631434A2 (es) | Derivados de piridina-carboxamida y su uso como plaguicidas | |
CO4930270A1 (es) | Derivados heterociclicos de acido carbonico su produccion y aplicacion como antagonistas de receptores deendotelina | |
PE46599A1 (es) | Metodo de uso de carbamatos y ureas neurotropicos | |
CO4950605A1 (es) | Nuevos derivados b-amino y b-azido de acido carbonico, su produccion y aplicacion como antagonistas de receptores de endotelina | |
AR018632A1 (es) | Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion. |